211 related articles for article (PubMed ID: 11159797)
1. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
2. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
7. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
9. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Zalma A; von Moltke LL; Granda BW; Harmatz JS; Shader RI; Greenblatt DJ
Biol Psychiatry; 2000 Apr; 47(7):655-61. PubMed ID: 10745059
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.
Walsky RL; Astuccio AV; Obach RS
J Clin Pharmacol; 2006 Dec; 46(12):1426-38. PubMed ID: 17101742
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
15. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
von Moltke LL; Greenblatt DJ; Granda BW; Giancarlo GM; Duan SX; Daily JP; Harmatz JS; Shader RI
J Clin Pharmacol; 2001 Jan; 41(1):85-91. PubMed ID: 11225565
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
[TBL] [Abstract][Full Text] [Related]
18. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
Sridar C; Kenaan C; Hollenberg PF
Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
[TBL] [Abstract][Full Text] [Related]
20. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
